The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
Nan Zhang(Anhui University of Traditional Chinese Medicine), Jianan Huang(Soochow University), Zeyi Liu(Soochow University), Dan Shen(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuanyuan Zeng(Sichuan University), Jianjie Zhu(Soochow University), Wenwen Du(Indiana University Bloomington)
Cited by 385
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF-β-induced epithelial-mesenchymal transition and metastasis by controlling TIF1γ in non-small cell lung cancer
|Molecular Cancer|2018|369
PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer
|International Journal of Clinical Oncology|2017|315
JAK/STAT3 signaling is required for TGF-β-induced epithelial-mesenchymal transition in lung cancer cells
|International Journal of Oncology|2014|314
Halide-Rich Synthesized Cesium Lead Bromide Perovskite Nanocrystals for Light-Emitting Diodes with Improved Performance
|Chemistry of Materials|2017|302